share_log

Shattuck Labs | 10-Q: Q2 2024 Earnings Report

Shattuck Labs | 10-Q: Q2 2024 Earnings Report

Shattuck Labs | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/02 04:24

Moomoo AI 已提取核心信息

Shattuck Labs reported Q2 2024 financial results with collaboration revenue increasing 704% to $1.6 million, driven by the Ono Pharmaceutical agreement and ImmunoGen partnership. Net loss was $21.6 million compared to $21.3 million in Q2 2023. Research and development expenses rose 5.7% to $19.2 million due to increased manufacturing costs for clinical trials.The company highlighted progress with its lead candidate SL-172154, sharing positive Phase 1B data in higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) at EHA 2024. Clinical responses showed improved rates compared to standard therapy, with manageable safety profile. Shattuck initiated additional randomized controlled cohorts in both HR-MDS and TP53 mutant AML to further evaluate efficacy.As of June 30, 2024, Shattuck had $105.3 million in cash and investments, which is expected to fund operations into 2026. The company continues to advance its ARC platform technology while exploring potential applications in autoimmune and inflammatory diseases through the Ono collaboration, which could provide up to $217.5 million in milestone payments plus royalties.
Shattuck Labs reported Q2 2024 financial results with collaboration revenue increasing 704% to $1.6 million, driven by the Ono Pharmaceutical agreement and ImmunoGen partnership. Net loss was $21.6 million compared to $21.3 million in Q2 2023. Research and development expenses rose 5.7% to $19.2 million due to increased manufacturing costs for clinical trials.The company highlighted progress with its lead candidate SL-172154, sharing positive Phase 1B data in higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) at EHA 2024. Clinical responses showed improved rates compared to standard therapy, with manageable safety profile. Shattuck initiated additional randomized controlled cohorts in both HR-MDS and TP53 mutant AML to further evaluate efficacy.As of June 30, 2024, Shattuck had $105.3 million in cash and investments, which is expected to fund operations into 2026. The company continues to advance its ARC platform technology while exploring potential applications in autoimmune and inflammatory diseases through the Ono collaboration, which could provide up to $217.5 million in milestone payments plus royalties.
Shattuck Labs 发布了2024年第二季度财务报告，其中合作营业收入比去年增加了704%，达到了160万美元，这得益于与Ono药品的协议和与ImmunoGen的合作。净亏损为2160万美元，而2023年第二季度为2130万美元。由于临床试验的制造成本增加，研发支出上涨了5.7%，达到1920万美元。该公司强调了其主要候选药物SL-172154的进展，在2024年EHA会议上分享了在高风险骨髓增生异常综合征（HR-MDS）和TP53突变的急性髓性白血病（AML）方面的积极第10亿阶段数据。临床反应显示与标准疗法相比，改善了反应率，并且安全性可控。Shattuck启动了额外的随机对照队列...展开全部
Shattuck Labs 发布了2024年第二季度财务报告，其中合作营业收入比去年增加了704%，达到了160万美元，这得益于与Ono药品的协议和与ImmunoGen的合作。净亏损为2160万美元，而2023年第二季度为2130万美元。由于临床试验的制造成本增加，研发支出上涨了5.7%，达到1920万美元。该公司强调了其主要候选药物SL-172154的进展，在2024年EHA会议上分享了在高风险骨髓增生异常综合征（HR-MDS）和TP53突变的急性髓性白血病（AML）方面的积极第10亿阶段数据。临床反应显示与标准疗法相比，改善了反应率，并且安全性可控。Shattuck启动了额外的随机对照队列，以进一步评估在HR-MDS和TP53突变的AML中的疗效。截至2024年6月30日，Shattuck拥有现金和投资10530万美元，预计可以支持其运营直到2026年。该公司继续推进其ARC平台科技，同时通过与Ono的合作探索在自身免疫和炎症疾病中的潜在应用，可能提供高达21750万美元的里程碑付款加上版税。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日